Research Analysts Issue Forecasts for STOK FY2025 Earnings

Stoke Therapeutics, Inc. (NASDAQ:STOK) – Cantor Fitzgerald increased their FY2025 earnings per share (EPS) estimates for Stoke Therapeutics in a research report issued to clients and investors on Thursday, March 20th. Cantor Fitzgerald analyst C. Duncan now expects that the company will earn $0.03 per share for the year, up from their previous forecast of ($2.40). Cantor Fitzgerald has a “Overweight” rating on the stock. The consensus estimate for Stoke Therapeutics’ current full-year earnings is ($2.01) per share.

Stoke Therapeutics (NASDAQ:STOK) last issued its quarterly earnings results on Monday, March 24th. The company reported ($0.18) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.56) by $0.38. The company had revenue of $22.61 million during the quarter, compared to analyst estimates of $4.20 million. Stoke Therapeutics had a negative net margin of 629.90% and a negative return on equity of 54.45%.

Other equities analysts also recently issued reports about the company. Chardan Capital restated a “buy” rating and set a $24.00 price target on shares of Stoke Therapeutics in a report on Wednesday, March 19th. Needham & Company LLC reaffirmed a “buy” rating and issued a $22.00 target price on shares of Stoke Therapeutics in a report on Tuesday, March 18th. Finally, HC Wainwright reiterated a “buy” rating and set a $47.00 price target on shares of Stoke Therapeutics in a report on Wednesday, March 19th. One investment analyst has rated the stock with a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, Stoke Therapeutics has an average rating of “Buy” and a consensus price target of $23.00.

Stoke Therapeutics Stock Up 1.7 %

Stoke Therapeutics stock opened at $8.29 on Monday. Stoke Therapeutics has a twelve month low of $6.29 and a twelve month high of $17.58. The company has a market capitalization of $448.31 million, a P/E ratio of -3.95 and a beta of 0.99. The stock’s 50 day moving average is $9.46 and its 200 day moving average is $11.35.

Insiders Place Their Bets

In related news, Director Edward M. Md Kaye sold 10,382 shares of the company’s stock in a transaction on Tuesday, March 18th. The shares were sold at an average price of $8.67, for a total transaction of $90,011.94. Following the completion of the transaction, the director now owns 148,253 shares in the company, valued at approximately $1,285,353.51. This represents a 6.54 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Barry Ticho sold 3,884 shares of the firm’s stock in a transaction that occurred on Tuesday, March 18th. The shares were sold at an average price of $8.67, for a total value of $33,674.28. Following the transaction, the insider now owns 63,962 shares of the company’s stock, valued at $554,550.54. This represents a 5.72 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 16,532 shares of company stock worth $143,332. Company insiders own 11.30% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in STOK. Bank of New York Mellon Corp boosted its holdings in Stoke Therapeutics by 1.4% during the 4th quarter. Bank of New York Mellon Corp now owns 93,195 shares of the company’s stock valued at $1,028,000 after acquiring an additional 1,330 shares during the period. Graham Capital Management L.P. lifted its holdings in shares of Stoke Therapeutics by 8.5% during the 4th quarter. Graham Capital Management L.P. now owns 18,634 shares of the company’s stock valued at $206,000 after purchasing an additional 1,453 shares during the last quarter. Gilder Gagnon Howe & Co. LLC grew its stake in Stoke Therapeutics by 2.0% during the 4th quarter. Gilder Gagnon Howe & Co. LLC now owns 92,546 shares of the company’s stock worth $1,021,000 after buying an additional 1,791 shares during the last quarter. Price T Rowe Associates Inc. MD grew its stake in shares of Stoke Therapeutics by 6.3% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 37,455 shares of the company’s stock worth $414,000 after acquiring an additional 2,215 shares during the last quarter. Finally, Rhumbline Advisers increased its stake in Stoke Therapeutics by 6.0% during the 4th quarter. Rhumbline Advisers now owns 49,374 shares of the company’s stock valued at $545,000 after purchasing an additional 2,787 shares in the last quarter.

Stoke Therapeutics Company Profile

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.